KEMİK İLİĞİNDE SPLENİK MARJİNAL ZON LENFOMA: BİR OLGU SUNUMU VE LİTERATÜRÜN GÖZDEN GEÇİRİLMESİ

Year 2020, Volume: 5 Issue: 2, 27 - 30, 01.08.2020

Arzu Tasdemir , Hatice Karaman , Fatma Şenel , İpek Özer

Abstract

Marjinal zon lenfomalar (MZL), sekonder lenfoid foliküllerin marjinal bölgesinde B lenfositlerinden kaynaklanan nadir görülen düşük dereceli B lenfomalarıdır. Nodüler Hodgkin lenfomalarının (NHL) %1'inden azını oluştururlar. Dünya Sağlık Örgütü'nün sınıflamasına göre marjinal bölge lenfomalar üç gruba ayrılır: ekstranodal MALT lenfoma, dalak MZL (SMZL) ve nodal MZL. Her üç grupta da kromozomal, genetik ve immünfenotibik benzerlikler vardır. SMZL genellikle kemik iliği ve dalak hilar lenf düğümleri tutan bir lenfomadır. Dalak periferik kan ve bazen karaciğer infiltrasyon gösterir, ve genellikle yaşamın altıncı on yılında ortaya çıkar. Tedavi için standart bir yaklaşım yoktur. Hastaların üçte ikisi tanı sırasında asemptomatiktir ve hastaların önemli bir kısmı başarılı bir şekilde splenektomi ile tedavi edilir.

Keywords

Splenik marjinal zon lenfoma, kemik iliği

Splenic Marginal Zone Lymphoma In Bone Marrow:A Case Report And Review Of The Literature

Abstract

Marginal zone lymphomas (MZL) are rare low-grade B lymphomas that originate from B lymphocytes in the marginal zone of the secondary lymphoid follicles. They comprise less than 1% of Nodular Hodgkin lymphomas (NHL). According to the World Health Organization’s classification, marginal zone lymphomas are divided into three groups: extranodal MALT lymphoma, splenic MZL (SMZL), and nodal MZL. All three groups have chromosomal, genetic, and immunophenotypic similarities. SMZL is a lymphoma that typically involves the bone marrow and hilar lymph nodes of the spleen. The spleen shows infiltration to peripheral blood and sometimes the liver, and usually occurs in the sixth decade of life. There is no standardized approach for treatment. Two-thirds of patients are asymptomatic during diagnosis, anda significant proportion of patients are successfully treated with a splenectomy.

Keywords

Splenic Marginal Zone Lymphoma, bone marrow, review

References

• Referans1: Hammer RD, Glick AD, Greer JP, Collins RD, Cousar JB. Splenic marginal zone lymphoma. A distinct B-cell neoplasm. Am J Surg Pathol. 1996 May;20(5):613-26.
• Referans2: Kent SA, Variakojis D, Peterson LC. Comparative study of marginal zone lymphoma involving bone marrow. Am J Clin Pathol. 2002 May;117(5):698-708.
• Referans3: Rosai J. Ackerman’s Surgical Pathology Vol: 2. Tenth edition, St. Louis, Mosby. 2011, pp 19091911.
• Referans4: Santos TSD, Tavares RS, Farias DLC. Splenic marginal zone lymphoma: a literature review of diagnostic and therapeutic challenges. Rev Bras Hematol Hemoter. 2017 Apr - Jun;39(2):146-154.
• Referans5: Swerdlow S.H., Campo E., Harris N.L., Jaffe E.S., Pileri S.A., Stein H. In: World Health Organization classification of tumours of haematopoietic and lymphoid tissues. 4th ed. Swerdlow S.H., Campo E., Harris N.L., Jaffe E.S., Pileri S.A., Stein H., et al., editors. International Agency for Research on Cancer (IARC); Lyon: 2008. International Agency for Research on Cancer (IARC). 422 p.
• Referans6: Behdad A., Bailey N.G. Diagnosis of splenic B-cell lymphomas in the bone marrow: a review of histopathologic, immunophenotypic, and genetic findings. Arch Pathol Lab Med. 2014;138(10):1295–1301.
• Referans7: Arcaini L., Merli M., Volpetti S., Rattotti S., Gotti M., Zaja F. Indolent B-cell lymphomas associated with HCV infection: clinical and virological features and role of antiviral therapy. Clin Dev Immunol. 2012;2012:1–10.
• Referans8: Gisbert JP, García-Buey L, Arranz R, Blas C, Pinilla I, Khorrami S, Acevedo A, Borque MJ, Pajares JM, Fernández-Rañada JM, Moreno-Otero R. The prevalence of hepatitis C virus infection in patients with non-Hodgkin's lymphoma. Eur J Gastroenterol Hepatol. 2004 Feb; 16(2):135-8.
• Referans9: Franco V, Florena AM, Stella M, Rizzo A, Iannitto E, Quintini G, Campesi G. Splenectomy influences bone marrow infiltration in patients with splenic marginal zone cell lymphoma with or without villous lymphocytes. Cancer. 2001 Jan 15;91(2):294-301.
• Referans10: The immunophenotype of splenic lymphoma with villous lymphocytes and its relevance to the differential diagnosis with other B-cell disorders. Matutes E, Morilla R, Owusu-Ankomah K, Houlihan A, Catovsky D. Blood. 1994 Mar 15;83(6):1558-62.
• Referans11: Bennett M, Schechter GP. Treatment of splenic marginal zone lymphoma: splenectomy versus rituximab. Semin Hematol. 2010 Apr;47(2):143-7.